A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer
Public ClinicalTrials.gov record NCT04461600. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multi-center, Open-label, Single Arm Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The current study is designed to evaluate the efficacy and safety of AL101 monotherapy in subjects with Notch-activated recurrent or metastatic TNBC; Notch activation will be determined by a Next Generation Sequencing (NGS) test.
Study identification
- NCT ID
- NCT04461600
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 18 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 14, 2020 (Actual)
- Primary completion
- Mar 23, 2022 (Actual)
- Completion
- Oct 11, 2022 (Actual)
- Last update posted
- Feb 12, 2024
2020 – 2022
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| Mayo Clinic | Phoenix | Arizona | 85054 | — |
| University of California at San Francisco | San Francisco | California | 94158 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| Comprehensive Hematology Oncology | St. Petersburg | Florida | 33709 | — |
| H. Lee Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| The University of Chicago | Chicago | Illinois | 60637 | — |
| Carle Clinic | Urbana | Illinois | 61801 | — |
| University of Louisville- James Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| Maryland Oncology Hematology | Columbia | Maryland | 20144 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Central Cancer Care | Bolivar | Missouri | 63613 | — |
| Memorial Sloan Kettering Cancer Center (MSKCC) | New York | New York | 10065 | — |
| University Health Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Charleston Oncology | Charleston | South Carolina | 29414 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04461600, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 12, 2024 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04461600 live on ClinicalTrials.gov.